Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174063/
https://www.ncbi.nlm.nih.gov/pubmed/32238470
http://dx.doi.org/10.1136/jitc-2019-000398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174063/
https://www.ncbi.nlm.nih.gov/pubmed/32238470
http://dx.doi.org/10.1136/jitc-2019-000398

Ejemplares similares